The Nucleic Acid Therapeutics CDMO Market is rapidly scaling, driven by the booming demand for nucleic acid–based therapies (like mRNA, siRNA, antisense oligonucleotides, gene editing). Pharmaceutical and biotech firms are increasingly relying on Contract Development & Manufacturing Organisations (CDMOs) to provide development, manufacturing and analytic services for these complex modalities. With rising gene-therapy pipelines, personalised medicine initiatives, and global outsourcing growth, the CDMO space is positioned for significant expansion.
The Global Nucleic Acid Therapeutics CDMO Market is projected to experience substantial growth from 8.01 USD Billion in 2024 to 28.62 USD Billion by 2035.The market is expected to grow at a compound annual growth rate of 12.27 percent from 2025 to 2035.
CDMOs specialising in nucleic acid therapeutics offer process development, GMP manufacturing, analytical services, formulation and fill/finish support—capabilities that many sponsors prefer to outsource given the steep technical, regulatory, and infrastructure demands. As therapy complexity grows and regulatory expectations heighten, the role of expert CDMOs becomes critical for time-to-market, cost-efficiency and quality compliance.
🔥 Unlock your FREE Sample Report now and stay ahead of competitive trends!:
https://www.marketresearchfuture.com/sample_request/33765
Key Market Drivers
- A surge in gene therapy, RNA-based treatments and nucleic acid platforms is creating a vast addressable base for CDMO services.
- Sponsors are increasingly outsourcing nucleic acid manufacturing to CDMOs to access specialised infrastructure, regulatory expertise and cost-efficient operations.
- Technological advances (automated synthesis, purification, high-throughput analytic platforms) are enabling CDMOs to scale capabilities, improving turnaround and capacity.
- Enhanced regulatory clarity for nucleic acid therapies and increasing prevalence of genetic/rare diseases are driving demand for CDMO support services.
- Geographic diversification of outsourcing: sponsors are exploring CDMO capacity in Asia-Pacific, Latin America and MEA to optimise cost and access skilled manufacturing.
Market Segmentation & Regional Highlights
The Nucleic Acid Therapeutics CDMO Market can be segmented by Therapy Type (mRNA, siRNA, plasmid DNA, gene therapy vectors), by Service Type (process development, manufacturing, analytical/quality control), by End User (pharmaceutical companies, biotech firms, academic & research institutes), and by Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa).
North America currently holds a dominant share due to its strong biotechnology ecosystem and sponsor presence. Europe remains a pivotal region for niche CDMO capacity and regulatory leadership. Asia-Pacific is forecasted to register fastest growth driven by emerging outsourcing hubs, favourable cost structures and expanding pharma R&D in countries like China and India.
💼 Purchase the full report for detailed forecasts, service & segment breakdowns, company profiles and regional competitive analysis:
https://www.marketresearchfuture.com/checkout?step=2&report_id=33765¤cy=one_user-USD
Competitive Landscape
The market features leading CDMOs and biomanufacturing service providers enhancing capabilities in nucleic acids. Key strategic moves involve infrastructure expansion (build-out of GMP plants for mRNA, plasmid DNA, viral vectors), partnerships with biotech sponsors, and integration of analytics and formulation services. Players are also expanding globally and offering end-to-end suites (from process development to fill/finish) to meet growing demand for turnkey solutions.
- Ipsen
- Lonza
- Cryoport
- Morrison and Foerster
- Ginkgo Bioworks
- Avid Bioservices
- Catalent
- Samsung Biologics
- WuXi AppTec
- Boehringer Ingelheim
- Arcturus Therapeutics
- Emergent BioSolutions
- Bend Research
- CureVac
- Fujifilm Diosynth Biotechnologies
Growth Opportunities & Trends
- Rising appetite for end-to-end CDMO solutions covering gene/RNA therapies and complex biologics.
- Expansion of CDMO footprint into emerging markets (Asia-Pacific, Latin America, MEA) to capture outsourcing growth and cost-efficient manufacturing.
- Increasing role of advanced manufacturing technologies (continuous manufacturing, modular plants, digital analytics) in nucleic acid production scaling.
- Growing demand for specialised services like plasmid DNA for gene therapy, next-generation mRNA platforms, CRISPR/viral vector support services.
- Strategic collaborations between CDMOs and innovators to co-develop technologies and create differentiated manufacturing offerings.
Browse In-depth Market Research Report (Pages, Charts, Tables, Figures) : https://www.marketresearchfuture.com/reports/nucleic-acid-therapeutics-cdmo-market-33765
Future Outlook
The Nucleic Acid Therapeutics CDMO Market is poised for strong growth through the mid-2030s as gene and RNA therapies become mainstream and outsourcing becomes the default model for many sponsors. CDMOs that invest in state-of-the-art infrastructure, regulatory compliance, global capability and service integration will be well-positioned. The shift towards personalised medicine, rare-disease therapies and high-value biologics underscores the long-term strategic relevance of this market.
➤➤Explore MRFR’s Related Ongoing Coverage In Healthcare Domain:
Inflammatory Bowel Therapeutic Market
Pharmacy Automation Devices Market
Pigmentation Disorders Treatment Market
Pigmented Lesion Treatment Market
Point of Care Sepsis Diagnostics Market
Polycystic Ovarian Syndrome Treatment Market
Portable Chromatography System Market
Intraoperative Neuromonitoring Market
Medical Affairs Outsourcing Market
Medical Clinical Nutrition Market
Medical Device Testing and Certification Market
Medical Holographic Display Market
